Thomas LeBlanc
Overview:
I am a medical oncologist, palliative care physician, and patient experience researcher, and serve as Chief Patient Experience and Safety Officer for the Duke Cancer Institute. My clinical practice focuses on the care of patients with hematologic malignancies, with a particular emphasis on myeloid conditions and acute leukemias including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs / MPDs, CML).
As founding Director of the Duke Cancer Patient Experience Research Program (CPEP), my research investigates common issues faced by people with cancer, including issues of symptom burden, quality of life, psychological distress, prognostic understanding, and treatment decision-making. This work aims to improve patients' experiences living with serious illnesses like blood cancers, including the integration of specialist palliative care services to provide an extra layer of support along with their comprehensive cancer care. More broadly, our team in CPEP conducts various studies of patient experience and outcomes issues in oncology, including retrospective chart review studies, comparative effectiveness work, prospective observational studies and registries, and qualitative research, along with efforts to facilitate the integration of patient-generated health data (PGHD) into routine cancer care processes, such as with electronic patient-reported outcome measures (ePROs) and other mobile health interventions (mHealth).
This work has led to recognition as an "Inspirational Leader under 40" by the American Academy of Hospice and Palliative Medicine (AAHPM), "Fellow" status from the Academy in 2016, the 2018 international "Clinical Impact Award" from the European Association for Palliative Care, and the AAHPM "Early Career Investigator" award in 2020. I served as 2017-18 Chair of the ASCO Ethics Committee, and currently Chair the Scientific Review Committee of the NIH/NINR-funded Palliative Care Research Cooperative Group (PCRC; www.palliativecareresearch.org). I have served on various national guideline panels for AML and for palliative/supportive care issues in oncology, and was inducted as a Fellow of the American Society of Clinical Oncology (FASCO) in 2021. To date I have published over 200 Medline-indexed articles, and several chapters in prominent textbooks of oncology and palliative medicine.
Positions:
Associate Professor of Medicine
Associate Professor in Population Health Sciences
Member of the Duke Cancer Institute
Education:
M.D. 2006
Intern
Resident
Chief Medical Resident
Fellowship, Hospice And Palliative Medicine
Fellow, Medical Oncology
Grants:
AC220-A-U302 trial
Prognostic understanding and decision-making in acute myeloid leukemia (AML)
Randomized Trial of Inpatient Palliative Care for Patients with Hematologic Malignancies
Understanding Barriers to Oral Therapy Adherence in Adult/Older-Adult AML Patients (429 Oral)
Palliative care and shared decision-making for patients with blood cancers
Publications:
An Analysis of Dasatinib Treatment Patterns in Patients with Chronic Myeloid Leukemia After Experiencing Pleural Effusion During Dasatinib Therapy.
In Their Own Words: A Qualitative Study of Coping Mechanisms Employed By Patients with Acute Myeloid Leukemia
The Patient Experience with Belantamab Mafodotin: Perspectives of Patients Receiving Treatment in Clinical Trials and in the Real-World
What Do Patients Think about Palliative Care? A National Survey of Hematopoietic Stem Cell Transplant Recipients.
Removing Transfusion Dependence As a Barrier to Hospice Enrollment (BRUOG-407)
Research Areas:
